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Recurrence after low-dose radioiodine ablation and 
recombinant human thyroid-stimulating hormone for 
differentiated thyroid cancer (HiLo): long-term results of an 
open-label, non-inferiority randomised controlled trial
Hakim-Moulay Dehbi, Ujjal Mallick, Jonathan Wadsley, Kate Newbold, Clive Harmer, Allan Hackshaw 
Summary
Background Two large randomised trials of patients with well-diferentiated thyroid cancer reported in 2012 (HiLo and 
ESTIMABL1) found similar post-ablation success rates at 6–9 months between a low administered radioactive iodine 
(¹³¹I) dose (1·1 GBq) and the standard high dose (3·7 GBq). However, recurrence rates following radioactive iodine 
ablation have previously only been reported in observational studies, and recently in ESTIMABL1. We aimed to 
compare recurrence rates between radioactive iodine doses in HiLo.
Methods HiLo was a non-inferiority, parallel, open-label, randomised controlled factorial trial done at 29 centres in the 
UK. Eligible patients were aged 16–80 years with histological conirmation of diferentiated thyroid cancer requiring 
radioactive iodine ablation (performance status 0–2, tumour stage T1–T3 with the possibility of lymph-node 
involvement but no distant metastasis and no microscopic residual disease, and one-stage or two-stage total 
thyroidectomy). Patients were randomly assigned (1:1:1:1) to 1·1 GBq or 3·7 GBq ablation, each prepared with either 
recombinant human thyroid-stimulating hormone (rhTSH) or thyroid hormone withdrawal. Patients were followed 
up at annual clinic visits. Recurrences were diagnosed at each hospital with a combination of established methods 
according to national standards. We used Kaplan-Meier curves and hazard ratios (HRs) for time to irst recurrence, 
which was a pre-planned secondary outcome. This trial is registered with ClinicalTrials.gov, number NCT00415233.
Findings Between Jan 16, 2007, and July 1, 2010, 438 patients were randomly assigned. At the end of the follow-up 
period in Dec 31, 2017, median follow-up was 6·5 years (IQR 4·5–7·6) in 434 patients (217 in the low-dose group and 
217 in the high-dose group). Conirmed recurrences were seen in 21 patients: 11 who had 1·1 GBq ablation and ten who 
had 3·7 GBq ablation. Four of these (two in each group) were considered to be persistent disease. Cumulative recurrence 
rates were similar between low-dose and high-dose radioactive iodine groups (3 years, 1·5% vs 2·1%; 5 years, 2·1% vs 
2·7%; and 7 years, 5·9% vs 7·3%; HR 1·10 [95% CI 0·47–2·59]; p=0·83). No material diference in risk was seen for T3 
or N1 disease. Recurrence rates were also similar among patients who were prepared for ablation with rhTSH and 
those prepared with thyroid hormone withdrawal (3 years, 1·5% vs 2·1%; 5 years, 2·1% vs 2·7%; and 7 years, 8·3% vs 
5·0%; HR 1·62 [95% CI 0·67–3·91]; p=0·28). Data on adverse events were not collected during follow-up.
Interpretation The recurrence rate among patients who had 1·1 GBq radioactive iodine ablation was not higher than 
that for 3·7 GBq, consistent with data from large, recent observational studies. These indings provide further 
evidence in favour of using low-dose radioactive iodine for treatment of patients with low-risk diferentiated thyroid 
cancer. Our data also indicate that recurrence risk was not afected by use of rhTSH.
Funding Cancer Research UK.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Thyroid cancer incidence has almost tripled in the 
USA in the past few decades, from 4·9 cases per 
100 000 individuals in 1975 to 14·3 per 100 000 in 2009.1 
Similar trends are observed in the UK,2 where incidence 
has more than doubled since the 1970s and is projected 
to rise by 74% between 2014 and 2035. Most cases are 
diferentiated thyroid cancer,3 with high 5-year survival 
rates of 90–95%.2,4
Most patients with diferentiated thyroid cancer have 
total or near-total thyroidectomy followed by radioactive 
iodine (¹³¹I) ablation and thyroid-stimulating hormone 
suppression therapy. Results of two large non-inferiority 
trials (HiLo5 and ESTIMABL16) published in 2012 have 
shown that a low administered radioactive iodine dose 
(1·1 GBq) for remnant ablation is as efective as the high 
dose (3·7 GBq), which was the standard for many years; 
the primary outcome was ablation success at 6–9 months 
after surgery. One of these trials, the HiLo trial, enrolled 
low-risk and intermediate-risk patients with diferentiated 
thyroid cancer. The low dose was associated with a lower 
rate of adverse events than the high dose, a shorter stay in 
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hospital isolation, and lower health-care costs.5,7 Although 
both trials provided deinitive evidence that the low dose 
had a similar ablation success rate as the high dose, 
whether this short-term outcome translates into longer-
term efects on recurrence risk remained an open question.
US and UK guidelines8,9 now recommend 1·1  GBq in 
selected low-risk patients, but these guidelines and 
others have commented on the lack of long-term follow-
up data from randomised trials in relation to recurrence 
rates.10 Available evidence for the efect of radioactive 
iodine dose on long-term recurrence rates comes from 
observational studies and only one randomised clinical 
trial, ESTIMABL1.11 Observational evidence comes 
primarily from studies in low-risk patients, comparing 
those treated with or without radioactive iodine ablation. 
Two systematic reviews of studies published up to 
200812,13 concluded that there was little or no diference 
between the low dose and high dose in either thyroid 
cancer recurrence or mortality risk, which was sub-
sequently conirmed by a systematic review14 of studies 
published between 2008 and 2014. Five recent studies 
have compared low-dose and high-dose radioactive 
iodine in patients at low and intermediate risk.15–19 They 
also provide no evidence of an increase in recurrence 
risk among patients treated with low-dose radioactive 
iodine. In the largest of these studies (comprising 
970 patients with a median follow-up of 5 years), the 
crude proportion of patients with a recurrence was lower 
in those who had a dose of 3·0 GBq or lower 
(four [2·6%] of 153 patients) than in those who had a 
dose higher than 3·0 GBq (61 [7·5%] of 817), even 
though the low-dose group had more patients with 
positive nodes (p=0·34 from the multivariable analysis). 
The investigators of the ESTIMABL111 randomised study 
recently reported their indings, based on 726 patients 
after a median follow-up of 5·4 years, which showed 
that recurrence risk was not inluenced by the ablation 
dose.
The HiLo study aimed to investigate whether low-dose 
radioactive iodine could be used instead of the high dose 
in low-risk or intermediate-risk patients, and whether 
patients could receive recombinant human thyroid-
stimulating hormone (rhTSH) before ablation instead of 
thyroid hormone withdrawal. Here, we report long-term 
follow-up data of patients in the HiLo trial to examine 
recurrence rates.
Methods
Study design and patients
HiLo was an open-label, non-inferiority, randomised 
controlled factorial trial done at 29 centres in the UK. 
The methods, study protocol, and results for the primary 
outcome5 have been published. Approval for the study 
was obtained from the national research ethics panel of 
the UK. All patients provided written informed consent 
to participate in the study.
Research in context
Evidence before this study
For patients with low-risk and intermediate-risk differentiated 
thyroid carcinoma, two large non-inferiority randomised trials 
(HiLo and ESTIMABL1) published in 2012 showed that a low 
administered radioactive iodine (¹³¹I) dose (1·1 GBq) had a 
similar ablation success rate after 6–9 months as the standard 
high dose (3·7 GBq) for thyroid remnant ablation. The effect of 
radioactive iodine dose on the risk of recurrence was only 
reported in observational studies. Most studies comprised 
low-risk patients, comparing those treated with or without 
radioactive iodine ablation. Three literature reviews, covering 
studies published until 2014, concluded that there is little or no 
difference between radioactive iodine and no radioactive iodine 
in thyroid cancer recurrence or mortality risk in low-risk 
patients. We searched PubMed for studies published in English 
between January, 2008, and December, 2017, comparing 
low-dose and high-dose radioactive iodine in low-risk and 
intermediate-risk patients. We used the keywords “differential 
thyroid cancer/carcinoma”, “radioiodine ablation”, and 
“low/high dose”. We identified five studies, with sample sizes 
ranging between 176 and 970 and median follow-up of at least 
5 years, suggesting that there is no increased recurrence risk in 
patients treated with low-dose radioactive iodine compared 
with high-dose radioactive iodine. There had been no data on 
recurrences from randomised trials until the follow-up study 
from ESTIMABL1, which indicated that recurrence was not 
related to the radioactive iodine dose. 
Added value of this study
In the HiLo trial, which comprised 434 patients, 21 clinically 
confirmed recurrences were seen during a median follow-up of 
6·5 years. The risk of thyroid cancer recurrence was not higher 
among patients who had 1·1 GBq than among those who had 
3·7 GBq ablation. Similarly, the recurrence risk was not 
materially higher among patients prepared for ablation with 
recombinant human thyroid-stimulating hormone than among 
those prepared with thyroid hormone withdrawal. We noted 
that several recurrences were seen after 5 years, which is worth 
consideration by clinicians treating patients for thyroid cancer, 
given that these patients are typically discharged from the clinic 
at 5 years in some centres. The few secondary primary cancers 
seen were balanced between the low-dose group and the 
high-dose group.
Implications of all the available evidence
Data from two randomised trials (HiLo and ESTIMABL1) and 
recent observational studies provide reliable evidence to further 
assure patients and clinicians of the benefits of using the low 
administered dose of radioactive iodine in selected patients. 
Guidelines can also now be strengthened on the basis of this 
evidence.
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Eligible patients were aged 16–80 years, with per for-
mance status of 0 to 2, histological conirmation of 
diferentiated thyroid cancer requiring radioactive 
iodine ablation, tumour stage T1 to T3 with the 
possibility of lymph-node involvement but no distant 
metastasis and no microscopic residual disease (ie, N0, 
NX, N1, and M0 in the tumour-node-metastasis [TNM, 
6th edition] staging system), and one-stage or two-stage 
total thyroid ect omy with or without prophylactic central 
lymph-node dissection.
Exclusion criteria were the presence of aggressive 
malignant variants, anaplastic or medullary carcinoma, 
pregnancy, severe coexisting conditions, previous 
cancer with limited life expectancy, previous ¹³¹I or ¹²³I 
pre-ablation scanning, and previous treatment for 
thyroid cancer except for surgery.
The full list of inclusion and exclusion criteria is 
available in the appendix. 
Randomisation and masking
Patients were randomly assigned to low-dose (1·1 GBq) 
or high-dose (3·7 GBq) radioactive iodine remnant 
ablation, each with either rhTSH (thyrotropin alfa 
[Thyrogen], provided by Genzyme) or thyroid hormone 
withdrawal, in a 1:1:1:1 randomisation ratio. Random -
isation was stratiied for centre, tumour stage, and nodal 
stage, and was done centrally (thus avoiding allocation 
concealment bias). This was an open-label trial, so it was 
not possible to mask the clinical staf or assessors.
Procedures
Patients were given an intramuscular injection of 
0·9 mg rhTSH on each of the 2 days before ablation. In 
the thyroid hormone withdrawal group, thyroxine 
(200 μg per day as the average dose) was discontinued 
4 weeks before ablation in 11 patients, and 
triiodothyronine (60 μg per day as the average dose) was 
discontinued for 2 weeks in 204 patients (the drug used 
was missing for four patients). Radioactive iodine 
ablation was administered 1 month to 6 months after 
surgery, at a dose of 1·1 GBq or 3·7 GBq depending on 
the study group allocation. Discharge from hospital 
isolation took place after satisfactory assessment of 
radiation risk and clinical conditions.
Following the assessment scan at 6–9 months after 
radioactive iodine ablation, all patients were meant to 
be seen in the clinic annually, according to the National 
Institute for Health and Care Excellence (NICE) 
guidance on head and neck cancers20 and British 
Thyroid Association (BTA) guidelines.9 Participating 
hospitals were actively contacted at least annually for 
patient outcomes. Data on adverse events were not 
collected during follow-up.
Outcomes
This report focuses on recurrence, which was a pre-
speciied secondary outcome of the HiLo trial, and was 
deined as any evidence of (usually structural) disease 
identiied during follow-up. Patients were diagnosed 
according to national standards using serum 
thyroglobulin and thyroglobulin antibody, ultrasound, 
ine needle aspiration cytology, radioactive iodine scans, 
PET-CT scans, and MRI, as applicable. These tests were 
used either together or one method (eg, serum 
thyroglobulin) could lead to further investigations 
(eg, ine needle aspiration). All patients had either ine 
needle aspiration or sensitive imaging (PET-CT or 
radioactive iodine scans). Four patients were diagnosed 
by both serum thyroglobulin and radioactive iodine, 
which might indicate some biochemical recurrences. 
Recurrence could also include persistent disease, 
relecting incomplete surgery or ablation failure. 
However, conirmation of persistent disease was di cult 
because ultrasound was not routinely used in the UK at 
the time of the trial as part of the 6–9-month assessment 
after ablation, so it was not possible to reliably ascertain 
whether a patient had a structural complete response 
(and was therefore disease-free) in order to distinguish 
these responses from genuine persistent disease. Second 
malignancies were recorded separately and conirmed 
locally with standard recom mended methods.
Statistical analysis
Recurrences are expected to be seen around 3–8 years 
after treatment, with the majority expected to occur 
before 5 years.12–14 Since patients were recruited to HiLo 
between 2007 and 2010, we decided to analyse recurrence 
using follow-up data up to Dec 31, 2017, to ensure that 
our median follow-up would be at least 5 years. Kaplan-
Meier curves were obtained for time to recurrence or 
death, with hazard ratios (HRs) from Cox proportional 
hazards regressions (the assumption of proportional 
hazards was met). For patients with multiple recurrences, 
Figure 1: Trial profile
rhTSH=recombinant human thyroid-stimulating hormone. *No information available after randomisation. 
3 lost to 
    follow-up*
1 lost to 
    follow-up*
220 assigned to low dose 1·1 GBq
110 assigned to 1·1 GBq
         with thyroid
         hormone
         withdrawal
110 assigned to 1·1 GBq 
         with thyrotropin
         alfa (rhTSH)
107 followed up;
         3 recurrences
110 followed up;
        8 recurrences
109 assigned to 3·7 GBq
         with thyroid
         hormone
         withdrawal
109 assigned to 3·7 GBq
         with thyrotropin
         alfa (rhTSH)
109 followed up;
         5 recurrences
108 followed up;
         5 recurrences
438 patients randomly assigned 
218 assigned to high dose 3·7 GBq
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the time to irst recurrence was used. Patients without 
recurrence were censored at their last follow-up visit. In 
addition to the standard statistical test for HRs, we did 
two non-inferiority tests. One test compared the 
proportion of patients with a recurrence between the 
radioactive iodine doses, with a margin of 5 percentage 
points for the diference in proportion. The other test 
was based on excluding an HR of 2·05 corresponding to 
an expected recurrence-free rate of 95% for 3·7 GBq and 
90% for 1·1 GBq. These non-inferiority margins were 
deined post hoc (because recurrence was a secondary 
endpoint) but were chosen to be consistent with other 
similar curative cancer trials in the past, and our non-
inferiority margin is in fact more stringent than that of 
recent non-inferiority trials that used margins of 
7 percentage points.21,22 We also did an analysis of 
recurrence stratiied by risk of recurrence and histology 
at baseline. A sensitivity analysis was done by excluding 
patients who had a further dose of radioactive iodine. All 
analyses were done with Stata, version 15.1. The statistical 
analyses for recurrence were not prespeciied in the 
original protocol.
This trial is registered with ClinicalTrials.gov, number 
NCT00415233.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had inal responsibility for 
the decision to submit for publication.
Results
Between Jan 16, 2007, and July 1, 2010, 438 patients were 
randomly assigned. By Dec 31, 2017, follow-up data were 
available for 434 patients (four patients had no follow-up 
data post-ablation; igure 1). Baseline characteristics are 
reported in table 1. Median follow-up time was 
78·4 months (range 0·3–127·3; IQR 54·4–91·3) or 6·5 
(IQR 4·5–7·6) years.
There were 21 reported recurrences as of Dec 31, 2017 
(table 2, appendix p 9). Following detailed review of 
reported cases, four patients (two in each group) were 
found to have persistent disease (all detected within 
1·3 years after ablation). These four patients were 
included as recurrences in the analyses. Also, there was 
one case initially reported by the hospital as a recurrence 
but later thought to be a possible secondary malignancy 
only in the low-dose group (results below are shown with 
and without this case). 
11 recurrences were reported in the low-dose group and 
ten in the high-dose group. Sites of recurrence in low-
dose patients were the thyroid bed (n=6), cervical lymph 
nodes (n=4), para-oesophageal lymph nodes (n=1), lung 
metastases (n=3), soft tissue metastases (n=1), and bone 
metastases (n=1); and those in high-dose patients were 
the thyroid bed (n=6), cervical lymph nodes (n=3), and 
lung metastases (n=1; appendix). One patient who had 
1·1 GBq (T3 stage/N0 at baseline) died from thyroid 
cancer, after recurrence in the thyroid bed with lung and 
bone metastases.
Two recurrences in the low-dose group and ive in the 
high-dose group were seen in patients who did not have 
an ablation success 6–9 months after radioactive iodine 
ablation (when success was deined as serum thyro-
globulin <2 ng/mL and scan uptake <0·1%). There were 
three recurrences in the low-dose group and four in the 
high-dose group among patients without ablation 
success deined using serum thyroglobulin only (ie, 
serum thyroglobulin ≥2 ng/mL). 
The overall recurrence rate was less than 9% by 8 years, 
which we consider to be largely due to specialist surgeons 
Recombinant human 
thyroid-stimulating hormone group
Thyroid hormone withdrawal group
1·1 GBq (n=110) 3·7 GBq (n=108) 1·1 GBq (n=107) 3·7 GBq (n=109)
Age, years 44 (34–55; 20–82) 44 (36–53; 21–76) 45  (38–53; 17–73) 43 (35–53; 18–77)
Sex
Women 77 (70%) 92 (85%) 79 (74%) 78 (72%)
Men 33 (30%) 16 (15%) 28 (26%) 31 (28%)
T stage
T1 32 (29%) 31 (29%) 33 (31%) 32 (29%)
T2 52 (47%) 52 (48%) 51 (48%) 50 (46%)
T3 25 (23%) 25 (23%) 23 (22%) 27 (25%)
Unreported 1 (1%) 0 0 0
N stage
N0 66 (60%) 62 (57%) 65 (61%) 63 (58%)
N1 17 (16%) 18 (17%) 15 (14%) 17 (16%)
Unknown 27 (25%) 28 (26%) 27 (25%) 29 (27%)
Surgery type
Near total 2 (2%) 0 0 1 (1%)
Completion 62 (56%) 71 (66%) 74 (69%) 58 (53%)
Total 46 (42%) 34 (32%) 31 (29%) 49 (45%)
Unknown 0 3 (3%) 2 (2%) 1 (1%)
Data are n (%) or median (IQR; range). 
Table 1: baseline characteristics of patients
Low-dose 
radioactive iodine 
group (1·1 GBq), 
n=11*
High-dose 
radioactive iodine 
group (3·7 GBq), 
n=10*
Fine needle aspiration or biopsy 6 7
Serum thyroglobulin 7 6
Ultrasound 5 6
Diagnostic radioactive iodine 
scan
3 3
PET-CT scan 6 4
MRI scan 2 1
Data are n. *Number of patients with recurrence. Each recurrence could be 
diagnosed with more than one method.
Table 2: Methods used to diagnose recurrence
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who performed the total thyroidectomies, and careful 
selection of patients for the trial by the local multi-
disciplinary teams. However, recurrences were still 
being seen after 5 years of follow-up.
Despite inclusion of intermediate-risk patients, recur-
rence rates were not materially higher in the low-dose 
radioactive iodine group than in the high-dose group. 
Kaplan-Meier cumulative recurrence rates were 
1·5% with 1·1 GBq versus 2·1% with 3·7 GBq at 3 years, 
2·1% versus 2·7% at 5 years, and 5·9% versus 7·3% at 
7 years (HR 1·10 [95% CI 0·47–2·59]; p=0·83; igure 2). 
Statistical tests for non-inferiority to exclude a 
5 percentage-point diference were signiicant for com-
par ing two recurrence proportions (pnon-inferiority=0·01), but 
not when based on the HR (pnon-inferiority=0·08; igure 2). 
The Kaplan-Meier curves largely overlapped (igure 2).
After excluding the potential secondary malignancy in 
the low-dose group, recurrences rates were 1·5% at 
3 years, 2·1% at 5 years, and 5·0% at 7 years (HR 0·99 
[95% CI 0·41–2·39]; p=0·99, pnon-inferiority=0·053 for the HR).
In a sensitivity analysis, we censored the four patients 
with persistent disease at the date of detection, instead of 
counting them as true recurrences. This analysis 
resulted in recurrence rates of 0·5% for 1·1 GBq versus 
1·1% for 3·7 GBq at 3 years, 1·1% versus 1·7% at 5 years, 
and 4·9% versus 6·3% at 7 years (HR 1·13 [95% CI 
0·43–2·92]; p=0·81).
Examination of the proportions of recurrences with 
respect to T stage and N stage provided additional 
evidence that 1·1 GBq was not associated with more 
recurrences than 3·7 GBq, even among patients with 
T3 tumours (table 3).
Results excluding the potential secondary malignancy 
are presented in the appendix (pp 4–6).
Among the 147 intermediate-risk patients (deined as 
either T3 or N1 according to the ATA 2015 risk classii-
cation system8) there were 12 recurrences (ive [7·1%] of 
70 in the low-dose group and seven [9·1%] of 77 in the 
high-dose group; p=0·67). In the remaining 287 low-risk 
patients there were nine recurrences (six [4·1%] of 147 in 
the low-dose group and three [2·1%] of 140 in the high-
dose group; p=0·35). 
A further dose of radioactive iodine (usually >3 GBq, 
mean dose approximately 5 GBq) was administered to 
22 (10%) of 217 patients in the low-dose (1·1 GBq) group 
and nine (4%) of 217 in the high-dose (3·7 GBq) group 
(p=0·02), because of thyroid remnant in 16 patients in 
the low-dose group and ive in the high-dose group (no 
re-ablations were done for recurrence according to 
information provided by the centres). These data were 
nearly the same as those in the original report (21 patients 
in the 1·1 GBq group vs nine in the 3·7 GBq group); no 
other additional doses were reported by the centres. 
Some of these further doses were due to overtreatment 
by some clinicians for faint temporary neck uptake 
following low-dose radioactive iodine treatment, which 
is of no signiicance and is well known within routine 
practice to disappear with time. In a sensitivity analysis 
excluding the 31 patients with further ablations, 
six recurrences were reported in the low-dose group and 
seven in the high-dose group, with recurrence rates 
of 1·1% for 1·1 GBq versus 1·1% for 3·7 GBq at 3 years, 
1·1% versus 1·7% at 5 years, and 3·7% versus 5·5% at 
7 years (HR 0·92 [95% CI 0·31–2·73]; p=0·87).
A conirmed second malignancy occurred in seven 
patients, 6 months to 7 years after ablation: in three 
patients in the low-dose group (plus the additional case 
mentioned previously, which was thought to be 
leiomyosarcoma or renal cancer) and in four in the high-
dose group. Two left-sided breast cancers and 
one squamous cell carcinoma of the loor of the mouth 
Figure 2: Kaplan-Meier curves showing risk of recurrence during follow-up 
(A) Kaplan-Meier curve of risk of recurrence according to radioactive iodine dose (3·7 GBq or 1·1 GBq). 
(B) Kaplan-Meier curve of risk of recurrence according to preparation for ablation with recombinant human 
thyroid-stimulating hormone (rhTSH) or thyroid hormone withdrawal. Kaplan-Meier curves appear to separate 
after about 7 years but there are only two events in total from this point. At 7 years, recurrence rates were 5·0% 
(95% CI 2·5–10·0) with thyroid hormone withdrawal and 8·3% (95% CI 4·5–15·3) with rhTSH, with overlapping 
confidence intervals.
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were reported in the low-dose group. In the high-dose 
group, there was one squamous cell carcinoma (unknown 
location), one bladder cancer, one mucosa-associated 
lymphoid tissue lymphoma, and one myelodysplastic 
syndrome. The second malignancy for one patient 
occurred after their thyroid cancer recurrence.
When comparing patients randomly assigned to be 
prepared for ablation with either rhTSH or thyroid 
hormone withdrawal, cumulative recurrence rates were 
1·5% for rhTSH versus 2·1% for thyroid hormone 
withdrawal at 3 years, 2·1% versus 2·7% at 5 years, and 
8·3% versus 5·0% at 7 years (HR 1·62 [95% CI 
0·67–3·91], p=0·28; igure 2). The Kaplan-Meier curves 
overlap for most of the follow-up. Tests for non-
inferiority were not signiicant for comparisons of 
two proportions (p=0·09) or for excluding an HR of 2·05 
(p=0·30). Furthermore, the 5-year recurrence rate was 
3·2% with 1·1 GBq and rhTSH versus 4·5% with 
3·7 GBq and thyroid hormone withdrawal (HR 1·56 
[95% CI 0·51–4·76]; p=0·44), although there were only 
13 events among 219 patients for this comparison. The 
appendix (p 7) shows Kaplan-Meier curves speciically 
for the comparison of 1·1 GBq with rhTSH versus 
3·7 GBq with thyroid hormone withdrawal, as well as the 
comparison of the four modalities of ablation (1·1 GBq 
with rhTSH, 1·1 GBq with thyroid hormone withdrawal, 
3·1 GBq with rhTSH, and 3·7 GBq with thyroid hormone 
withdrawal). No clear diferences were seen between 
these modes of ablation.
We also found no material diference in recurrence 
rates between patients with diferent histologies at diag-
nosis (appendix p 8). In 229 patients with papillary 
thyroid cancer there were ten recurrences: four (3·4%) 
of 116 were given the low dose and six (5·3%) of 113 given 
the high dose. Among 171 patients with follicular and 
Hürthle cell cancers there were seven recurrences: in 
ive (6·0%) of 83 patients given the low dose and two 
(2·3%) of 88 given the high dose. The HR for comparison 
of these two histological groups was 1·01 (95% CI 
0·38–2·66; p=0·98). Histology was not reported for 
34 patients, in whom there were four recurrences. 
Discussion
Long-term follow-up data from the HiLo randomised 
trial show that the low administered radioactive iodine 
dose is not associated with a higher risk of recurrence 
than the high dose, and nor is the risk of recurrence 
higher with rhTSH than with thyroid hormone 
withdrawal. The proportion of patients with recurrence 
in this study (21 [5%] of 434) is in line with the 
recurrence rate expected for low-risk and intermediate-
risk patients with diferentiated thyroid cancer.8 These 
results extend our earlier conclusions that low-dose 
radioactive iodine is non-inferior to high-dose 
radioactive iodine in terms of ablation success rate in 
selected patients with low-risk and intermediate-risk 
diferentiated thyroid cancer.5,6 Indeed, ablation success 
is sometimes considered a marker of recurrence or 
disease-related mortality.23 Recurrence has several 
consequences for patients, and studies suggest that 
even though patients with diferentiated thyroid cancer 
have an excellent prognosis, several feel fear or anxiety 
over the potential for recurrence.24,25
Recurrences were still seen in HiLo beyond 5 years 
(ie, the Kaplan-Meier curves in igure 2 were not lattening 
out). In some centres in routine practice, patients are 
discharged from the clinic at around 5 years, under the 
assumption that recurrences will be rare after this time. 
Indeed, in HiLo there were 134 patients (72 in the low-
dose group and 62 in the high-dose group) without 
recurrence who were expected to have had a last clinic 
date more than 5 years after their 6–9-month ablation 
assessment scan, but did not; many of these patients 
might have been discharged back to primary care. Our 
indings suggest that slightly longer follow-up might be of 
value in some cases, which has practical signiicance for 
clinicians treating patients for thyroid cancer. A simpliied 
surveillance protocol with the use of serum thyroglobulin 
alone, which is easy and inexpensive, might be considered 
after 5 years of follow-up for some or even all patients. 
Variations in national follow-up guidelines and in their 
implementation by individual clinicians, inclusion of 
intermediate-risk patients in HiLo, and variation in serum 
thyroglobulin assay sensitivity in diferent centres might 
explain the diference in longer-term recurrences seen in 
HiLo and by others. Nevertheless, our indings are 
consistent with those of another multicentre study in Italy 
in which three (23%) of 13 recurrences were observed at 
5–8 years of follow-up.26
ESTIMABL1, the other randomised trial published 
alongside HiLo, reported no noticeable diference in 
outcomes in low-risk patients with diferentiated thyroid 
cancer.11 After a median follow-up of 5·4 years, 11 of 
726 patients had either persistent structural disease, 
serum thyroglobulin greater than 1 ng/mL, or indeter-
minate indings on neck ultrasonography without biopsy; 
of these, six had received 1·1 GBq and ive had 3·7 GBq, 
including two cases of lymph-node recurrence. 
Low-dose radioactive 
iodine group
High-dose radioactive 
iodine group
T1 3/65 (5%) 2/63 (3%)
T2 5/103 (5%) 5/102 (5%)
T3 3/48 (6%) 3/52 (6%)
N0 8/131 (6%) 4/125 (3%)
N1 2/32 (6%) 6/35 (17%)
Nx 1/54 (2%) 0/57 (0%)
AJCC/UICC=American Joint Committee on Cancer/Union for International Cancer 
Control. p=0·98 for the association between radioactive iodine dose and recurrence 
rate, stratified by either T or N stage. T stage unreported in one patient.
Table 3: Recurrence by T stage and N stage at baseline (with AJCC/UICC 
TNM 6th edition)
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Key strengths of the HiLo trial were the longer follow-
up (6·5 years) and hence more recurrences (n=21), which 
were clinically conirmed with UK guidelines. A major 
design diference between ESTIMABL1 and HiLo was 
that ESTIMABL1 only enrolled low-risk patients 
(only two of the 752 patients had T3 disease), whereas 
HiLo enrolled intermediate-risk patients (100 of 438 had 
T3 disease). Therefore, only HiLo showed recurrence 
data speciically for T3 patients and showed that there 
was no material diference between low-dose and high-
dose radioactive iodine. Inclusion of these intermediate-
risk patients in HiLo is therefore of particular interest 
to the thyroid cancer community. We also provide 
Kaplan-Meier curves for recurrence, allowing clinicians 
and guideline authors to see when recurrences occurred 
and that the curves overlap. Finally, the multicentre 
design of HiLo increases the generalisability of the 
indings.
The main limitation of our study was that it was not 
powered to assess recurrence (a secondary outcome), 
which would have required a much larger trial. Therefore, 
although the test for non-inferiority based on comparing 
proportions was signiicant, the test based on the HR 
was not (p=0·08). However, the Kaplan-Meier curves 
overlapped throughout, strengthening our conclusions. 
Another limitation is that there was no standard follow-
up schedule speciied in the trial protocol because this 
would have required additional inancial resources for 
hospitals to adhere to. UK centres follow standard 
guidelines from NICE and the BTA, but these guidelines 
are based on low-quality evidence about long-term follow-
up, so there was some expected variability in the use of 
diagnostic tests across the centres when identifying 
recurrences in HiLo.
Before ESTIMABL1 and HiLo, the evidence for 
recurrence rates after radioactive iodine came only from 
obser vational studies. Although some individual studies 
reported higher recurrence rates with the low dose, 
two systematic reviews conducted up to 200812,13 concluded 
that there was little or no diference in either thyroid 
cancer recurrence or mortality in low-risk patients, 
among those with or without radioactive iodine ablation. 
This inding was conirmed by the systematic review of 
Lamartina and colleagues,14 which updated previous 
reviews by including studies published in 2008–14. Later 
studies are likely to be more reliable because of the 
increased sensitivity of modern tests and diagnostic 
methods for inding and conirming thyroid cancer 
recurrence. Five recent observational studies have 
compared low-dose and high-dose radioactive iodine 
(appendix p 11).15–19 In the largest of these (970 patients 
and 65 recurrences), the crude proportion of patients with 
a recurrence was lower in those who had 3·0 GBq or 
lower (four [2·6%] of 153) than in those who had greater 
than 3·0G Bq (61 [7·5%] of 817), even though the high-
dose group had more patients with positive nodes (p=0·34 
from the multivariable analysis). In two studies (with 
225 and 204 patients), no diferences were shown 
(two [2·4%] of 85 recurrences at the low dose versus 
three [2·1%] of 140 at the high dose, p=0·87; and 
seven [8·7%] of 80 at the low dose versus seven [5·6%] of 
124 at the high dose, p=0·57). The fourth study reported 
no recurrences by 7 years in 176 patients. The ifth study 
(comprising 698 low-risk patients) also found no 
diference in recurrence rates overall, but hinted at a 
higher thyroid cancer mortality in the subgroup of 
patients aged 45 years or older who had 0·6–2·0 GBq 
(compared with those who had >2·0 GBq to 7·8 GBq); 
however, this analysis was based on seven events.19 An 
important limitation of these observational studies is that 
they were single-centre studies (except for one that 
comprised two hospitals18), in contrast to our national 
randomised multicentre trial (29 centres). Large, recent 
observational studies of low-risk and intermediate-risk 
patients with diferentiated thyroid cancer have compared 
recurrence between patients who did or did not have 
radioactive iodine ablation.27–34 Although these studies 
have variable follow-up times, they too have low rates of 
recurrence (<10% over 5–10 years; appendix p 12). None 
of these published studies shows a clear detriment to 
patients if they did not have ablation, providing further 
support for the indings from HiLo, because these studies 
are expected to show larger diferences in recurrence 
rates, if they exist, than those comparing high and low 
doses of radioactive iodine.
The combination of recent large observational studies 
and long-term follow-up of two randomised trials (HiLo 
and ESTIMABL1) represents comprehensive and 
deinitive evidence that low-dose radioactive iodine is an 
acceptable therapy for patients with diferentiated thyroid 
cancer. The next step is to show whether radioactive 
iodine ablation can be avoided completely in patients at 
very low risk. Two large prospective trials are ongoing, the 
IoN trial (NCT01398085) and ESTIMABL2 (NCT01837745), 
both of which involve randomly assigning selected low-
risk patients to have either 1·1 GBq radioactive iodine 
ablation or no radioactive iodine ablation, with disease-
free survival as a major endpoint.
In 2012, the European Medicines Agency extended the 
licence indication for rhTSH, on the basis of the results 
for ablation success, allowing it to be used with 1·1 GBq. 
But the agency requested long-term data about recurrences 
be made available at a later date. Data from the HiLo trial 
(showing Kaplan-Meier curves for recurrence) provide 
this evidence to further support the use of rhTSH with 
low-dose radioactive iodine.
In conclusion, after a median follow-up of more than 
6 years in HiLo, the recurrence rate was similar between 
patients who had low-dose radioactive iodine ablation 
and those who had the high dose (and between those 
prepared for ablation with rhTSH and those who under-
went hormone withdrawal). Together with the results of 
the ESTIMABL1 trial and contemporary observational 
studies, reliable evidence is now available to strengthen 
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guidelines and further assure patients and clinicians of 
the beneits of using the low administered dose.
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